H.C. Wainwright analyst Brandon Folkes assumed coverage of Sagimet Biosciences (SGMT) with a Buy rating and $29 price target The company is has a potential best-in-class fatty acid synthase inhibitor platform with “multiple shots on goal” across a number of diseases, including near-term clinical catalysts in metabolic dysfunction-associated steatohepatitis and dermatology, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- 3 Best Stocks to Buy Now, 7/25/2025, According to Top Analysts
- Sagimet Biosciences initiated with a Buy at Canaccord
- Largest borrow rate increases among liquid names
- 3 Best Stocks to Buy Now, 6/23/2025, According to Top Analysts
- Buy Rating for Sagimet Biosciences Driven by Promising Clinical Data and Market Potential of Denifanstat